#pharmaceuticals

#pharmaceuticals

We've created a small molecule chemical which gets in your body very well. It can mimic the effects of the peptide and can be taken more conveniently any time of day without any food or water restrictions.

Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.

'They bite things to investigate and end up exposed to substances', lead author Natascha Wosnick told Science News.

President Donald Trump announced that Americans would see lower prescription drug prices after his administration reached deals with nine top drug manufacturers on Friday. Trump was joined at the White House Friday by the leaders of nine of the world's largest pharmaceutical manufacturersto announce that they have agreed to offer many of their flagship drugsat heavily discounted most favored nation's prices. Some of the drugs mentioned include those for diabetes, asthma, and blood thinning.

The milestone US-UK deal announced this month on pharmaceuticals, which will mean the NHS pays more for medicines in exchange for a promise of zero tariffs on the industry, still lacks a legal footing beyond top lines contained in two government press releases. Concerns over the basis of the agreement have been heightened by Washington's decision to suspend the 31bn tech prosperity deal, which had been hailed as a generational step-change in our relationship with the US.

A world-beating deal, boasts the science minister, Patrick Vallance. It paves the way for the UK to become a global hub for life sciences, claims the business secretary, Peter Kyle, with the government press release adding: Tens of thousands of NHS patients will benefit. Presented with such triumph, His Majesty's press is up on its hindlegs. Happy pills ran a laudatory editorial in the Times, while the Daily Mail sportingly thanked Donald Trump for his US lifeline for UK pharma. Britain 1, America 0!

Consumer giant Kimberly-Clark, which makes Huggies diapers and Kleenex tissues, is buying the company that makes Tylenol and Band-Aids in one of the biggest mergers of the year. The deal, worth almost $49 billion, comes at a particularly difficult time for Tylenol-maker Kenvue, after the Trump administration linked acetaminophen the active ingredient in this common painkiller to autism. The assertions came despite a lack of clear scientific evidence, and Kenvue has called them simply false.

A slow week with little important economic news (other than yesterday's Bureau of Labor Statistics report on falling first-time unemployment filings) got busy in a hurry on Friday, with the U.S. Commerce Department revealing the personal consumption expenditures price index (PCE) increased 0.3% in August. The new data clocks the annual U.S. inflation rate at 2.7%. Volatile food and energy prices, once excluded to give a "core" inflation rate, rose 0.2% to 2.9%.

Neural networks are some of the most promising artificial intelligence (AI) models. These systems process data similarly to the human brain, passing information through a complex network of nodes in the same way information goes through layers of neurons. That makes them capable of solving complicated problems in minimal time, which is particularly advantageous in the medical industry. Drug discovery is a vital but challenging process.

Organizations that ignore Generative AI may face significant opportunity risks including loss of revenue, particularly in high-stakes industries such as pharmaceutical research and legal.

Ozempic is projected to achieve $17 billion in sales for 2024 and almost $5 billion in the first quarter of 2025, highlighting its commercial success.